As the first generation of antigen-specific immune tolerance therapies enter clinics and with excitement around recent partnerships, IPOs and investments reaching new heights, now is the time for an industry forum for large pharma, pioneering biotech and academia to be able to meet and share knowledge.
The 1st Antigen-Specific Immune Tolerance Drug Development Summit is that forum, and has a brand-new agenda that can help you successfully overcome the scientific, product development and commercialization challenges currently being faced.
The 1st Antigen-Specific Immune Tolerance Drug Development Summit is that forum, and has a brand-new agenda that can help you successfully overcome the scientific, product development and commercialization challenges currently being faced.
